At Blueberry Therapeutics

Nano Medicine icon large

At Blueberry Therapeutics, drug discovery always starts with a thorough appreciation of patients’ needs. We then seek out innovative new approaches to develop medicines that meet these needs.

We are currently exploiting state-of-the-art nanodelivery platforms to develop therapies for a range of diseases. Developing this “nanomedicine” approach will, we believe, open up huge opportunities to more rapidly develop safe new medicines and exploit currently “undruggable” targets to treat a wide range of diseases.

Nanoparticle formulation greatly enhances delivery
Nano Medicine icon large

Our nanodelivery systems greatly enhance drug delivery and efficacy and allow us to modulate drug targets with peptide, protein and small molecule therapies.

Nanopolymer Delivery Systems Chart

We utilize a highly effective drug delivery system based on a well-described nanopolymer with over 30 years of safe human use. This system rapidly self-assembles with both small and large molecules (e.g. proteins, peptides and nucleic acids) and “packages” them into nanoparticles. These nanoparticles greatly enhance cellular delivery into both mammalian and bacterial cells.

Use of this technology allows Blueberry to develop therapies against well-validated targets in new ways. It also lets us over-come the limitations of some current therapies by improving drug solubility, cellular delivery and efficacy. Finally, the ability of our nanopolymer system to deliver protein and peptides in active confirmations into cells opens up exciting new possibilities for “intracellular biologics” capable of tackling attractive approaches to disease treatment that are currently perceived to be “undruggable” by conventional small molecule treatments.

Drugs in our pipeline
Patents and exclusive licences
Billion dollars in commercial potential

Blueberry Therapeutics Ltd Blueberry Therapeutics, Mereside, Alderley Park, Nether Alderley,
Macclesfield, Cheshire, SK10 4TG.